Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia

Emerging Infectious Diseases
Mitchell J SchwaberHoward S Gold

Abstract

We conducted a retrospective study of the clinical aspects of bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with heterogeneously reduced susceptibility to vancomycin. Bloodstream MRSA isolates were screened for reduced susceptibility by using brain-heart infusion agar, including 4 mg/L vancomycin with and without 4% NaCl. Patients whose isolates exhibited growth (case-patients) were compared with those whose isolates did not (controls) for demographics, coexisting chronic conditions, hospital events, antibiotic exposures, and outcomes. Sixty-one (41%) of 149 isolates exhibited growth. Subclones from 46 (75%) of these had a higher MIC of vancomycin than did their parent isolates. No isolates met criteria for vancomycin heteroresistance. No differences in potential predictors or in outcomes were found between case-patients and controls. These data show that patients with vancomycin-susceptible MRSA bacteremia have similar baseline clinical features and outcomes whether or not their bacterial isolates exhibit growth on screening media containing vancomycin.

References

Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Mar 11, 1998·Lancet·R A HoweA P MacGowan
Dec 10, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G BierbaumH G Sahl
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S S WongK Y Yuen
Jan 11, 2000·The Journal of Antimicrobial Chemotherapy·R A HoweA P Macgowan
Jul 25, 2000·The Journal of Infection·P R Chadwick, S L Wooster
Oct 6, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J BurnieS D'arcy
Dec 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S K Fridkin
Apr 11, 2001·Emerging Infectious Diseases·F C TenoverM V Lancaster
Oct 5, 2001·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·G A OliveiraE M Mamizuka
Mar 2, 2002·The Lancet Infectious Diseases·K Hiramatsu
Aug 9, 2002·Canadian Journal of Microbiology·Nevio Cimolai
Nov 7, 2002·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)

❮ Previous
Next ❯

Citations

Feb 1, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B P HowdenM L Grayson
Apr 12, 2011·Medicina clínica·María Isabel Morosini, Rafael Cantón
Feb 7, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin P HowdenM Lindsay Grayson
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Amir KhosrovanehRiad Khatib
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose M EguiaHenry F Chambers
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald P Levine
Jun 15, 2012·JAAPA : Official Journal of the American Academy of Physician Assistants·Roy A Borchardt, Kenneth V I Rolston
Mar 28, 2008·Southern Medical Journal·Donald P Levine
May 1, 2009·Journal of Clinical Microbiology·Aroonlug LulitanondKeiichi Hiramatsu
May 5, 2011·Genome Génome / Conseil National De Recherches Canada·GongXin Yu
Jan 1, 2008·Infection and Drug Resistance·Federico PerezRobert A Bonomo
Jul 14, 2011·Emerging Infectious Diseases·Jose Maria AguadoFernando Chaves
Jan 14, 2004·Emerging Infectious Diseases·Stephen G WeberYehuda Carmeli
Oct 27, 2004·Emerging Infectious Diseases·Jiun-Ling WangKeiichi Hiramatsu
Sep 18, 2008·Journal of Applied Microbiology·T P T CushnieA J Lamb
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Scott D Pope, Andrew M Roecker
Oct 13, 2007·Expert Opinion on Pharmacotherapy·Evelina Tacconelli, Maria A Cataldo
Feb 18, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C NonhoffM J Struelens

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Software Mentioned

SAS

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Amir KhosrovanehRiad Khatib
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Patrick G P CharlesM L Grayson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Patrick G P CharlesM L Grayson
© 2022 Meta ULC. All rights reserved